Bank of America
IKT icon

Bank of America’s Inhibikase Therapeutics IKT Stock Holding History

Bank of America’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542K Buy
322,704
+276,293
+595% +$491K ﹤0.01% 4851
2025
Q4 		$95.1K Buy
46,411
+29,309
+171% +$46.6K ﹤0.01% 5646
2025
Q3 		$27.7K Sell
17,102
-2,114
-11% -$3.66K ﹤0.01% 6999
2025
Q2 		$37.5K Sell
19,216
-25,810
-57% -$50.5K ﹤0.01% 6893
2025
Q1 		$98.6K Buy
45,026
+40,517
+899% +$102K ﹤0.01% 6496
2024
Q4 		$14.7K Buy
4,509
+4,456
+8,408% +$11.1K ﹤0.01% 6910
2024
Q3 		$69 Buy
53
+11
+26% +$15 ﹤0.01% 7783
2024
Q2 		$51 Buy
+42
New +$72 ﹤0.01% 7835
2024
Q1 		– Sell
-62
Closed -$79 – 7941
2023
Q4 		$79 Buy
+62
New +$64 ﹤0.01% 7438
2023
Q1 		– Sell
-7
Closed -$20 – 8016
2022
Q4 		$20 Buy
+7
New +$28 ﹤0.01% 7988
2022
Q1 		– Sell
-5
Closed – – 8486
2021
Q4 		$0 Buy
+5
New +$55 ﹤0.01% 8396

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's IKT Position: Q1 2026 in Review

Bank of America increased its Inhibikase Therapeutics (IKT) stake by 595% in Q1 2026, buying an estimated $491K and bringing the position to 322,704 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4851.

Bank of America first reported a position in IKT in Q4 2021 and has held it in 11 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Bank of America held 322,704 shares of Inhibikase Therapeutics worth $542K as of Q1 2026.
  • Bank of America bought 276,293 Inhibikase Therapeutics shares in Q1 2026, an estimated $491K.
  • Inhibikase Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4851 holding.
  • Bank of America first reported a position in Inhibikase Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.